Abstracts tagged "Medicare"

Abstract Number: 1053 • 2013 ACR/ARHP Annual Meeting
Physician Proclivity To Use Oral Glucocorticoids Among Rheumatoid Arthritis Patients
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: It is unclear if the elevated risks of adverse events in rheumatoid arthritis (RA) patients are due to use of biologics or DMARDs, glucocorticoids…
Abstract Number: 1054 • 2013 ACR/ARHP Annual Meeting
Use Of Oral and Subcutaneous MTX In a Commercially Insured Rheumatoid Arthritis Population
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang³, Lang Chen⁴, Huifeng Yun⁵, Michael H. Schiff⁶, Timothy Beukelman⁷ and Seth Ginsberg⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Creaky Joints, New York, NY
Background/Purpose: Methotrexate (MTX) is the most commonly used medication in rheumatoid arthritis (RA), although use of oral and subcutaneous (SQ) preparations in real-world settings has…
Abstract Number: 1048 • 2013 ACR/ARHP Annual Meeting
Generalizability Of a U.S. Rheumatoid Arthritis Registry: A Comparison Of Participants’ Vs. Non-Participants’ Characteristics
Jeffrey R. Curtis¹, Lang Chen², Huifeng Yun³, Leslie R. Harrold⁴, Jeffrey D. Greenberg⁵ and Joel M. Kremer⁶, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: Observational registries provide a valuable complement to clinical trials yet might suffer from limited generalizability referent to the desired population of interest. We compared…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].